Cell-free DNA (cfDNA) is easily accessible in peripheral blood and can be used as
biomarkers for cancer diagnostics, prognostics, and therapeutics. The applications of cfDNA …

Precision oncology is predicated upon the ability to detect specific actionable genomic
alterations and to monitor their adaptive evolution during treatment to counter resistance …

Since its discovery in human blood plasma about 70 years ago, circulating cell-free DNA
(cfDNA) has become an attractive subject of research as noninvasive disease biomarker …

Highlights•Cell-free nucleic acids in body fluids contain tumour fragments that can be
profiled for prognostic and diagnostic information for the management of cancer.•cfDNA …

An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …

Circulating cell-free DNA (cfDNA) has been suggested as a cancer biomarker. Several
studies assessed the usefulness of quantitative and qualitative tumor-specific alterations of …

Breast cancer is the most prevalent and leading cause of mortality worldwide among
women. Cell-free DNA (cfDNA) analysis is an alternative quantitative approach to …

BACKGROUND: Cell-free DNA (CFDNA) in the plasma/serum of patients with cancer
demonstrates tumour-associated genetic alterations, offering possibilities for diagnosis …

Liquid biopsy can quantify and qualify cell-free (cfDNA) and tumour-derived (ctDNA) DNA
fragments in the bloodstream. CfDNA quantification and mutation analysis can be applied to …